Lee E-Chiang, Owen Michael
Kymab Ltd, Meditrina, Cambridge, UK.
Methods Mol Biol. 2012;901:137-48. doi: 10.1007/978-1-61779-931-0_8.
In 2006, panitumumab, the first fully human antibody generated from transgenic mice, was approved for clinical use by the US Food and Drug Administration (FDA). Since then, a further seven such antibodies have been approved. In this chapter, we discuss how transgenic mice technologies can provide a powerful platform for creating human therapeutic antibodies.
2006年，首个源自转基因小鼠的全人源抗体帕尼单抗被美国食品药品监督管理局（FDA）批准用于临床。自那时起，又有另外七种此类抗体获得批准。在本章中，我们将讨论转基因小鼠技术如何能够为生产人类治疗性抗体提供一个强大的平台。
